Merck Earnings Preview: Lower Profit, Higher Sales Expected

Filed under: Earnings Reports, Forecasts, Merck and Co (MRK)

Global pharmaceutical giant Merck & Co. Inc. (MRK), whose brands include Claritin, Coppertone, Lotrimin, Propecia, Singulair and Vytorin, is scheduled to discuss its fourth-quarter and full-year financial results in a conference call Monday, Feb. 16, at 8:00 AM (ET), hosted by CEO Richard T. Clark and CFO Peter N. Kellogg. A live webcast of the call will be available at the company's website.

During the three months that ended in December, Merck merged with Schering-Plough, appointed a chief medical officer and announced a quarterly dividend. Analysts surveyed by Thomson Reuters are looking for earnings for that period of $0.78 per share, down from $0.90 per share in the previous quarter and $0.87 per share a year ago. But revenue for the fourth quarter is expected to have jumped 60.8% from a year ago to $9.7 billion.

Continue reading Merck Earnings Preview: Lower Profit, Higher Sales Expected

Merck Earnings Preview: Lower Profit, Higher Sales Expected originally appeared on BloggingStocks on Mon, 15 Feb 2010 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Full story at http://www.pheedcontent.com/click.phdo?i=be8b3c9c51f68920dfffd721e914f34a